Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362541057> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W4362541057 endingPage "1879" @default.
- W4362541057 startingPage "1879" @default.
- W4362541057 abstract "Abstract Nectin-4 is a Ca2+ independent immunoglobulin-like protein that is primarily involved in cell-cell adhesion. Nectin-4 is overexpressed in several tumor types, including breast, lung, urothelial, colorectal, pancreatic, and ovarian cancers. Overexpression of Nectin-4 is associated with multiple aspects of tumor progression such as proliferation, angiogenesis, epithelial to mesenchymal transition, metastasis, DNA repair and tumor relapse. This overexpression is correlated with poor prognosis, making Nectin-4 an attractive target for developing new therapeutic strategies for cancer. As a result, a substantial number of antibody drug conjugates targeting Nectin-4 are under development. Most of these therapies, however, display a high rate of drug related toxicities accentuating the need for alternative approaches for anti-cancer therapeutics targeting Nectin-4. We leveraged BioAtla’s Conditionally Active Biologic (CAB) platform to develop a dual CAB T cell engager (TCE) bispecific antibody targeting Nectin-4 and CD3 receptors (CAB-Nectin-4 x CAB-CD3 bispecific antibody). The dual CAB Nectin-4 x CD3 bispecific antibody was engineered to bind with high affinity to both Nectin-4 and CD3 receptor antigens under conditions that mimic the acidic tumor microenvironment, but with lower binding activity in physiological (alkaline) conditions. In vitro and in vivo efficacy data for a dual-CAB Nectin-4 x CD3 bispecific antibody will be presented. Our data will demonstrate that the dual-CAB bispecific antibody promotes cytotoxicity of Nectin-4-expressing cancer cells in vitro and induces complete tumor regression in vivo. Further, the dual CAB Nectin-4 x CD3 bispecific antibody has higher potency in inducing primary T cell activation measured by means of cytokine release and cancer cell cytotoxicity under acidic conditions compared to the non-CAB benchmark bispecific antibody. Citation Format: Matthew Lucas, Ana Paula Cugnetti, Haizhen Liu, Charles Xing, Jing Wang, Patricia McNeeley, Christina Wheeler, Solmarie Joyner, Kyrie Johnson, Kathryn Woodard, Wei Zhou, Cathy Chang, Gerhard Frey, William J. Boyle, Jay M. Short. A novel dual CAB nectin-4 x CD3 bispecific antibody targeting solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1879." @default.
- W4362541057 created "2023-04-06" @default.
- W4362541057 creator A5006461698 @default.
- W4362541057 creator A5013794878 @default.
- W4362541057 creator A5013989679 @default.
- W4362541057 creator A5020231301 @default.
- W4362541057 creator A5021648163 @default.
- W4362541057 creator A5027946171 @default.
- W4362541057 creator A5031275782 @default.
- W4362541057 creator A5031797785 @default.
- W4362541057 creator A5037677450 @default.
- W4362541057 creator A5061736733 @default.
- W4362541057 creator A5064033877 @default.
- W4362541057 creator A5066268969 @default.
- W4362541057 creator A5068685609 @default.
- W4362541057 creator A5076278244 @default.
- W4362541057 creator A5083808471 @default.
- W4362541057 date "2023-04-04" @default.
- W4362541057 modified "2023-09-30" @default.
- W4362541057 title "Abstract 1879: A novel dual CAB nectin-4 x CD3 bispecific antibody targeting solid tumors" @default.
- W4362541057 doi "https://doi.org/10.1158/1538-7445.am2023-1879" @default.
- W4362541057 hasPublicationYear "2023" @default.
- W4362541057 type Work @default.
- W4362541057 citedByCount "0" @default.
- W4362541057 crossrefType "journal-article" @default.
- W4362541057 hasAuthorship W4362541057A5006461698 @default.
- W4362541057 hasAuthorship W4362541057A5013794878 @default.
- W4362541057 hasAuthorship W4362541057A5013989679 @default.
- W4362541057 hasAuthorship W4362541057A5020231301 @default.
- W4362541057 hasAuthorship W4362541057A5021648163 @default.
- W4362541057 hasAuthorship W4362541057A5027946171 @default.
- W4362541057 hasAuthorship W4362541057A5031275782 @default.
- W4362541057 hasAuthorship W4362541057A5031797785 @default.
- W4362541057 hasAuthorship W4362541057A5037677450 @default.
- W4362541057 hasAuthorship W4362541057A5061736733 @default.
- W4362541057 hasAuthorship W4362541057A5064033877 @default.
- W4362541057 hasAuthorship W4362541057A5066268969 @default.
- W4362541057 hasAuthorship W4362541057A5068685609 @default.
- W4362541057 hasAuthorship W4362541057A5076278244 @default.
- W4362541057 hasAuthorship W4362541057A5083808471 @default.
- W4362541057 hasConcept C114684123 @default.
- W4362541057 hasConcept C147483822 @default.
- W4362541057 hasConcept C1491633281 @default.
- W4362541057 hasConcept C150903083 @default.
- W4362541057 hasConcept C159654299 @default.
- W4362541057 hasConcept C167672396 @default.
- W4362541057 hasConcept C185592680 @default.
- W4362541057 hasConcept C203014093 @default.
- W4362541057 hasConcept C207001950 @default.
- W4362541057 hasConcept C23327873 @default.
- W4362541057 hasConcept C2776107976 @default.
- W4362541057 hasConcept C3020616263 @default.
- W4362541057 hasConcept C502942594 @default.
- W4362541057 hasConcept C55493867 @default.
- W4362541057 hasConcept C71924100 @default.
- W4362541057 hasConcept C85789140 @default.
- W4362541057 hasConcept C86803240 @default.
- W4362541057 hasConceptScore W4362541057C114684123 @default.
- W4362541057 hasConceptScore W4362541057C147483822 @default.
- W4362541057 hasConceptScore W4362541057C1491633281 @default.
- W4362541057 hasConceptScore W4362541057C150903083 @default.
- W4362541057 hasConceptScore W4362541057C159654299 @default.
- W4362541057 hasConceptScore W4362541057C167672396 @default.
- W4362541057 hasConceptScore W4362541057C185592680 @default.
- W4362541057 hasConceptScore W4362541057C203014093 @default.
- W4362541057 hasConceptScore W4362541057C207001950 @default.
- W4362541057 hasConceptScore W4362541057C23327873 @default.
- W4362541057 hasConceptScore W4362541057C2776107976 @default.
- W4362541057 hasConceptScore W4362541057C3020616263 @default.
- W4362541057 hasConceptScore W4362541057C502942594 @default.
- W4362541057 hasConceptScore W4362541057C55493867 @default.
- W4362541057 hasConceptScore W4362541057C71924100 @default.
- W4362541057 hasConceptScore W4362541057C85789140 @default.
- W4362541057 hasConceptScore W4362541057C86803240 @default.
- W4362541057 hasIssue "7_Supplement" @default.
- W4362541057 hasLocation W43625410571 @default.
- W4362541057 hasOpenAccess W4362541057 @default.
- W4362541057 hasPrimaryLocation W43625410571 @default.
- W4362541057 hasRelatedWork W1974142213 @default.
- W4362541057 hasRelatedWork W2033739428 @default.
- W4362541057 hasRelatedWork W2040191638 @default.
- W4362541057 hasRelatedWork W2048473435 @default.
- W4362541057 hasRelatedWork W2053424985 @default.
- W4362541057 hasRelatedWork W2092538248 @default.
- W4362541057 hasRelatedWork W2229562627 @default.
- W4362541057 hasRelatedWork W2748952813 @default.
- W4362541057 hasRelatedWork W2899084033 @default.
- W4362541057 hasRelatedWork W2574914054 @default.
- W4362541057 hasVolume "83" @default.
- W4362541057 isParatext "false" @default.
- W4362541057 isRetracted "false" @default.
- W4362541057 workType "article" @default.